NCT01479764

Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)

Effect of Sugammadex Compared With Usual Care for Reversal of Neuromuscular Blockade Induced by Rocuronium on Incidence of Residual Blockade at PACU Entry

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 154 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will compare the incidence of residual neuromuscular blockade in participants who undergo reversal of neuromuscular blockade with sugammadex compared to those who undergo reversal of neuromuscular blockade with usual care (neostigmine/glycopyrrolate).

Conditions

• Surgical Procedures, Elective

Interventions

Type	Name	Description
DRUG	Sugammadex	sugammadex, intravenous (IV) bolus, 2 or 4 mg/kg depending on level of neuromuscular recovery
DRUG	Neostigmine	neostigmine, per usual practice
DRUG	Glycopyrrolate	glycopyrrolate per usual practice

Timeline

• Start date: 2011-12-02
• Primary completion: 2012-10-26
• Completion: 2012-11-05
• First posted: 2011-11-24
• Last updated: 2017-06-06
• Results posted: 2013-12-31